Case report

Squamous cell carcinoma of the breast: About a case

R.E.L. Qasseh, Z. Sami, M. Moutahir, M. Herrad, M. Benhassou, M. Ennachit, M. El Keroumi *

Department of Gynecological-Mammary Surgery, Mohammed VI Center for Cancer Treatment Faculty of Medicine and Pharmacy, Hassan II University, Ibn Rochd University Hospital, Casablanca, Morocco

ARTICLE INFO

Keywords:
Squamous cell carcinoma
Breast
Diagnosis
Treatment
Prognosis

ABSTRACT

Squamous cell carcinoma of the breast is a rare metaplastic breast tumor whose histogenesis is controversial. Its prevalence is estimated between 0.06 % and 0.2 % of all breast neoplasms [1]. The histogenesis remains obscure. The clinical aspects are not specific. Squamous cell carcinoma is characterized by a rapid evolution and by an uncodified treatment [2].

The objective of our work, by reporting a new case of primary squamous cell carcinoma of the breast, is to specify through a literature review some characteristics of this particular form of breast cancer.

Squamous cell carcinoma of the breast is a rare tumor belonging to the heterogeneous group of metaplastic carcinomas. The clinical and radiological presentations are not specific. The prognosis.

1. Introduction

Squamous cell carcinoma of the breast is a rare metaplastic breast tumor whose histogenesis is controversial. Its prevalence is estimated between 0.06 % and 0.2 % of all breast neoplasms [1]. The histogenesis remains obscure. The clinical aspects are not specific. Squamous cell carcinoma is characterized by a rapid evolution and by an uncodified treatment [2].

The objective of our work, by reporting a new case of primary squamous cell carcinoma of the breast, is to specify through a literature review some characteristics of this particular form of breast cancer.

The work has been reported with respect to the SCARE 2020 criteria [19].

2. Observation

A 42-year-old patient followed for type 2 diabetes on insulin therapy with no personal or family history of neoplastic disease consulted for a mass in the left breast evolving 6 months before admission. Examination found a 6 cm mass in the inferior-internal quadrant of the mobile left breast with respect to both planes, without inflammatory signs or nipple discharge associated with a 3 cm ipsilateral axillary lymphadenopathy (Fig. 1).

Mammography found type 3 breast density with the presence of two increased opacity in the left lower-inner quadrant with irregular spiculated contours (Fig. 2).

On ultrasound, we noted the presence of a hypoechoic lesion in the lower inner left quadrant with irregular contours measuring 1.6 × 2.2 cm associated with a cyst with echogenic content measuring 1.1 × 1.3 cm in regular course; rated ACR Birads 5 (Fig. 3).

Breast mass biopsy confirmed the presence of SBR grade III invasive squamous cell metaplastic breast carcinoma, hormone receptors were not expressed, as well as HER 2 amplification, Ki67 was at 40 % with tumor cells express CK5/6.

The extension assessment made of abdominal and pelvic CT scan and bone scintigraphy, was negative.

The patient had benefited from a patey of the left breast, after discussion in multidisciplinary consultation meeting, with the anatomicopathologic study: The Scarff-Bloom et Richardson (SBR) grade III invasive squamous cell metaplastic breast carcinoma the size was 5 cm, positive vascular embolism, resection limits were healthy, axillary lymph node dissection was positive: 2 lymphadenopathy affected from 6 (2 N+/6 N). According to the TNM classification our patient is classified: p T2N1.

The patient is then put on chemotherapy: 3 courses of Anthracyclines and 3 courses of Taxanes, then radiotherapy 40 Grays; with a follow-up of 30 months.

3. Discussion

Primary squamous cell carcinoma of the breast is rare. Its prevalence is estimated between 0.06 % and 0.2 % [1].

It is part of the heterogeneous group of metaplastic breast carcinomas.

* Corresponding author at: Mohammed el bahi Imm 161 palmier Maarif, 20340 Casablanca, Morocco.
E-mail address: rajaqelqasseh@gmail.com (M. El Keroumi).

https://doi.org/10.1016/j.ijscr.2022.107589
Received 30 May 2022; Received in revised form 29 August 2022; Accepted 29 August 2022
Available online 31 August 2022
2210-2612/© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
According to the WHO, squamous cell carcinoma of the breast belongs to infiltrating ductal carcinomas comprising metaplastic changes of the squamous cell type, in the absence of any other ductal or mesenchymal neoplastic component and of any other focus of distant squamous cell carcinoma [3].

The metaplastic origin of these tumors is well established but their histogenesis is controversial.

For some, the origin is glandular, for others it is myoepithelial [2]. Squamous cell carcinoma of the breast affects women between the ages of 30 and 80 with a predominance at the age of 55 [4].

Clinically, the tumor generally manifests as a mass comparable to a benign tumor with an average size of 5 cm and extremes of 2 to 16 cm. The evolution is usually rapid. It can also be revealed by mastodynia, inflammatory signs, nipple discharge, retraction of the nipple, ulcerations of the skin opposite or sometimes a breast abscess [5].

Lymph node involvement is rarely associated [6]. Our patient presented with ipsilateral axillary adenopathy.

Radiologically, the aspect is not specific. It is generally a rounded mass, without a spicule, partially irregular with a cystic or necrotic center, which explains the pseudocystic or abscessed appearance found [7].

Calcifications can be seen within necrotic squamous tissue [8]. Ultrasound breast may show a hypoechoic mass with cystic components resembling a complex breast cyst [9].

Histologically, squamous cell carcinoma of the breast has an architecture and cytonuclear characteristics identical to other squamous cell carcinomas developing in another site [9]. Immunohistochemistry shows expression of epithelial tumor cells of high molecular weight cytokeratins, in particular CK14 CK5/6 and CK17 [11].

Hormone receptors are generally negative as well as HER 2 [12]; Our patient was also triple negative as in the literature.

Given the rarity of this type of tumor, the appropriate treatment is poorly codified [13]. The treatment is similar to that of infiltrating ductal carcinomas of the breast, it usually involves mastectomy with axillary lymph node dissection followed by chemotherapy and radiotherapy [4]. Indeed, neoadjuvant chemotherapy is not justified to consider a conservative treatment since its results are mediocre [18].

Most chemotherapy regimens have combined 5-fluorouracil and cisplatin with some success [14].

Given the usual negativity of hormone receptors, hormone therapy has little place in the therapeutic arsenal for squamous cell carcinoma of the breast [10].

The prognostic factors are mainly represented by the size of the tumor, lymph node involvement [15]. The presence of a fusiform component, necrosis or cellular acantholysis is considered predictors of an unfavorable outcome [16].

The prognosis of breast squamous cell carcinoma remains pejorative with the occurrence during the first five years of metastases in the lung, liver, bone or brain [17]. The average survival at 5 years is estimated between 50 and 63 % [2].
4. Conclusion

Squamous cell carcinoma of the breast is a rare tumor belonging to the heterogeneous group of metaplastic carcinomas. The clinical and radiological presentations are not specific. The prognosis remains poor. Treatment is based on surgery with axillary lymph node dissection. Adjuvant treatment combines radiotherapy and chemotherapy, the type of which remains to be specified, hence the interest of studies allowing a better knowledge of their evolutionary profile for a better codification of their management.

Funding
None.

Ethical approval
I declare on my honor that the ethical approval has been exempted by my establishment.

Consent
Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient.

Author contribution
El Qasseh Rajaa: Corresponding author writing the paper
Fares el arab Khadija: study concept
Moutahir Maria: study concept
Benhessou Mustapha: study concept
Ennachit Mohammed: study concept
El. Karroumi Mohammed: correction of the thesis and operating surgeon.

Registration of research studies
researchregistry2464.

Guarantor
DR EL QASSEH RAJAA.

Declaration of competing interest
The authors declare having no conflicts of interest for this article.

References
[1] I. Aparicio, A. Martínez, G. Hernández, Squamous cell carcinoma of the breast, Eur J Obstet Gynecol Reprod Biol. 137 (2008) 222–226.
[2] K. Tayeb, I. Saadi, M. Kharmash, K. Hadadi, E. El Ghazi, A. Mansouri, et al., Primary squamous cell carcinoma of the breast. Report of three cases, Cancer Radiother J Soc Francaise Radiother Oncol. 6 (6) (2002) 366–368.
[3] P.P. Rosen, in: Atlas of Tumor Pathology, Tumors of the Mammary Gland, Third series 7, AFIP, 1993, pp. 26–27.
[4] B. Belabidia, S. Selliami, A. Hamdouzi, H. Abbassi, Squamous cell carcinoma of the breast review of the literature: illustrated by the report of a case, J. Gynecol. Obstet. Biol. Reprod. (Paris) 31 (1) (2002) 34–39.
[5] M. Ziyadi, M. Boujoual, H. Raiteb, M.A. Babahabib, J. Kouach, D.R. Moussaoui, et al., Squamous cell carcinoma of the breast: report of a case and review of the literature, Pan Afr. Med. J. 24 (2016), 213-213.
[6] A. Abida, D. Kacimi, M. El Youssfi, S. Bargach, Carcinome métaplasique du sein: a propos de deux cas, Int. J. Innov. Appl. Stud. 23 (3) (2018) 285–289.
[7] N. Rokutanda, Y. Iino, T. Yokoe, M. Maemura, J. Horiguchi, H. Takei, et al., Primary squamous cell carcinoma of the breast during lactation: a case report, Jpn. J. Clin. Oncol. 30 (6) (2000) 279–282.
[8] T. Shigekawa, H. Yuda, K. Sato, S. Ueda, H. Asakawa, R. Shigenaga, et al., Squamous cell carcinoma of the breast in the form of an intracystic tumor, Breast Cancer 14 (1) (2007) 109-112.
[9] A. Trabelsi, N. Boujelbene, O. Gharbi, S. Rammeh, B. Sriha, S. Korbi, Carcinome épidermoïde primitif pur du sein. Approche clinico-pathologique, therapeutique et evolutive, Imag. Femme 18 (1) (2008) 55–57.
[10] K. Okada, K. Makihara, M. Okada, E. Hayashi, S. Fukino, T. Fukata, et al., A case of primary squamous cell carcinoma of the breast with rapid progression, Breast Cancer 7 (2) (2000) 160–164.
[11] J. Mychaluk, M. Baron, É. Fendrinier, S. Laberge, J. Gondry, R. Fauvet, Carcinomes épidermoïdes primitifs du sein: etude clinique et revue de la litterature, Bull. Cancer (Paris) 99 (7-8) (2012) 771–778.
[12] E. Konuk, E. Arpaci, S. Ergen, E. Isik, G. Yurdakan, Primary squamous cell carcinoma of the breast: a case report in a review of current literature, J. Oncol. Sci. 3 (1) (2017) 29–31.
[13] S. Carbon, R.L. Alvarez, A. Lamacchia, A.A. Gil, R.M. Hernandez, J.L.L. Guerra, et al., Primary squamous cell carcinoma of the breast: a rare case report, Rep. Pract. Oncol. Radiother. 17 (6) (2012) 363–366.
[14] J. Liu, Y. Yu, J. Sun, S. He, X. Wang, J. Yin, et al., Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast, Breast Cancer Res. Treat. 149 (1) (2015) 133–140.
[15] M.M. Melbouf, N. El Amrani, H. Mathieu-Daude, J.B. Dubois, Les carcinomes épidermoides du sein: a etude clinique et revue de la litterature, Bull. Cancer (Paris) 29 (4) (2003) 386–389.
[16] K.A. Behranwala, N. Nasiri, N. Abdullah, P.A. Trott, G.P.H. Gui, Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome, Eur. J. Surg. Oncol. 29 (2) (2003) 160–165.
[17] P. Benoist, A. Mureau, Y. Joueidi, F. Arbion, A. Vilde, G. Body, et al., Management and prognosis of pure primary squamous cell carcinoma of the breast, J. Gynecol. Obstet. Hum. Reprod. 47 (7) (2018) 275–280.
[18] B. Hennessey, S. Krishnamurthy, S. Giordano, et al., Squamous cell carcinoma of the breast, J. Clin. Oncol. 23 (31) (2005 Nov 1) 7827–7835.
[19] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, pour le groupe SCARE, La ligne directrice SCARE 2020 : mise à jour des lignes directrices du SCARE (Consensus Surgical Case Report), International Journal of Surgery 84 (2020) 226–230.